Arthritis & Rheumatology News and Research

Latest Arthritis & Rheumatology News and Research

A novel approach to treating rheumatoid arthritis

Rheumatoid arthritis is a crippling disease and is caused when the body's own immune system attacks the joints and leads to chronic pain and inflammation. A team from Newcastle University funded by Arthritis Research UK have discovered an approach which could effectively prevents white blood cells from reaching the joints and causing more damage.

7 Mar 2012

Pharmspective releases first knowledge management application: ClearView

Pharmspective, LLC today announced the release of its first knowledge management application - ClearView - specifically developed to analyze provisions in the health care reform law and their impact on key pharma customer decision makers who influence product adoption.

7 Mar 2012

USA Wrestling to gain access to NYU Langone's orthopaedic experts

USA Wrestling, the national governing body for amateur wrestling in the United States, announced today that the Department of Orthopaedic Surgery at NYU Langone Medical Center is an official sponsor and medical consultant, through September 2014.

6 Mar 2012

Anthera continues Phase 2b PEARL-SC clinical study in SLE patients

Anthera Pharmaceuticals, Inc., a biopharmaceutical company developing drugs to treat serious diseases including cardiovascular and autoimmune disorders, today announced the continuation of the Phase 2b PEARL-SC clinical study following an interim analysis of all safety and efficacy data.

5 Mar 2012

Study: Bioavailability similar among four subcutaneous IgG preparations

Data presented by CSL Behring today suggest that the bioavailability of immunoglobulin G (IgG) therapies is consistent when patients with primary immunodeficiencies switch from one IgG product to another by the subcutaneous route.

5 Mar 2012

AARDA hopes to educate public on autoimmune diseases during March

March is National Autoimmune Diseases Awareness Month, and the American Autoimmune Related Diseases Association (AARDA) is working to educate the public on risk factors, prevalence, and the severe lack of awareness surrounding autoimmune diseases.

3 Mar 2012

New ACR classification criteria for polymyalgia rheumatica

The American College of Rheumatology has released the first classification criteria for polymyalgia rheumatica - aimed at helping physicians identify patients with this condition, which occurs in persons aged 50 years or older who have recent onset of pain in the shoulders, neck and hips along with other inflammatory symptoms not explained by an alternate diagnosis.

2 Mar 2012

Volunteers wanted for chronic pain research

A professor studying the subject of chronic pain is inviting people from all walks of life to help with her research.

2 Mar 2012

Preliminary results from Genentech's ACTEMRA monotherapy study on RA

Genentech, a member of the Roche Group, today announced that preliminary results from the ADACTA (ADalimumab ACTemrA) study showed that patients who received ACTEMRA (tocilizumab) as monotherapy achieved a significantly greater reduction in disease activity after 24 weeks than those given adalimumab monotherapy.

2 Mar 2012

Conference on follow-on versions of complex drugs

On March 9, the New York Academy of Sciences will present "Scientific Considerations for Complex Drugs in Light of Established Regulatory Guidance." This full-day conference will explore current definitions, global scientific and regulatory hurdles, and future challenges for follow-on versions of complex drugs.

2 Mar 2012

Ten physicians indicted in alleged $250 million fraud scheme

As has been the trend in some recent health care fraud cases, the physicians were not the ringmasters. Instead, the indictments allege that they were fronts for others -; primarily immigrants from the former Soviet Union.

2 Mar 2012

Akeso Medical Imaging starts clinical study for proof of concept of imaging device for rheumatoid arthritis disease activity monitoring and control

Akeso Medical Imaging BV, announces today the start of a clinical study with their novel imaging device for assessment of joint inflammation in patient with rheumatoid arthritis (RA). In this proof of concept study, Akeso’s imaging device will be compared to other methods to assess disease status, such as the DAS-28 score, Ultrasound and in some cases MRI. The study will be performed at the University Medical Center Utrecht (UMC Utrecht) in cooperation with Regional Rheumatology Centre Eindhoven (RRC). Seventy subjects will be included; sixty RA patients with varying degrees of inflammation of the joints of hands and wrists at the time of examination and a control group of ten subjects.

1 Mar 2012

Cyclotides discovery may open up new possibilities for immune suppression

A team of researchers at the MedUni Vienna, together with scientists from the University Hospital of Freiburg, has decoded a mechanism in cyclic plant peptides, known as cyclotides, from the family of coffee plants (Rubiaceae) that could open up new possibilities for immune suppression.

1 Mar 2012

Creabilis initiates CT327 Phase IIb trial in psoriasis vulgaris

Creabilis SA, a European biotechnology company specialising in the development of treatments for dermatology, inflammation and pain, today announced the start of the Phase IIb global clinical trial of its lead product CT327 in patients with psoriasis vulgaris. Recruitment is progressing well.

29 Feb 2012

TUT creates first biodegradable joint implant for arthritic patients

Tampere University of Technology (TUT), Finland, has been the first in the world to develop biodegradable joint implant, RegJoint-. The implant is used in the treatment of osteoarthritis and rheumatoid arthritis.

29 Feb 2012

Dompé enters definitive agreement to acquire Anabasis

Dompé, one of Italy's leading biopharmaceutical companies, announced today that it has entered into a definitive agreement to acquire 100% of Anabasis Srl, a privately held Italian research and development biopharmaceutical company, focused on ocular diseases.

28 Feb 2012

Savient fourth quarter net loss increases to $30.9 million

Savient Pharmaceuticals, Inc. reported financial results for the three months ended December 31, 2011, which reflect the Company's continuing investment in the U.S. launch of KRYSTEXXA(pegloticase). Savient ended the quarter with approximately $170 million in cash and short-term investments, a decrease of $33 million for the quarter.

27 Feb 2012

The Lancet publishes Takeda's TAK-875 Phase 2 data on type 2 diabetes

Phase 2 clinical data of an investigational type 2 diabetes therapy, TAK-875 of Takeda Pharmaceutical Company Limited, were published online first in The Lancet.

27 Feb 2012

FDA panel votes in favor of earlier rejected anti-obesity drug Qnexa

Qnexa took a step closer to approval on Wednesday, when outside advisers to the U.S. Food and Drug Administration voted 20-to-2 in favor of approval. The panel also recommended the company conduct a study to scrutinize even more closely any risk of heart problems. That study may be required after the drug is approved. Should the FDA ask for further data on heart risks before any approval, it would delay Qnexa's launch further.

26 Feb 2012

Depressive symptoms of fathers lead to mental health problems in children

Voluminous research literature attests to the multiple negative consequences of maternal depression and depressive symptoms for the health and development of children. In contrast, there is a profound paucity of information about depressive symptoms in fathers according to a follow up study by NYU School of Medicine researchers in the February 23rd online edition of Maternal and Child Health Journal.

24 Feb 2012